Human papillomavirus types 16, 18, and 31 serostatus and prostate cancer risk in the prostate cancer prevention trial

Cancer Epidemiology Biomarkers and Prevention

Volumn 19, Issue 2, 2010, Pages 614-618

  Sutcliffe, Siobhan ^a   Viscidi, Raphael P ^b   Till, Cathee ^e   Goodman, Phyllis J ^e   Hoque, Ashraful M ^f   Hsing, Ann W ^g   Thompson, Ian M ^h   Zenilman, Jonathan M ^b   De Marzo, Angelo M ^b,c   Platz, Elizabeth A ^c,d  

^a USA   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

^c DEPARTMENT OF PATHOLOGY   (United States)

^d JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^e Fred Hutchinson Cancer Research Center   (United States)

^f UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^g NATIONAL CANCER INSTITUTE   (United States)

^h Mays Cancer Center at UT Health San Antonio   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN G ANTIBODY;

ADULT; ARTICLE; CANCER PREVENTION; CANCER RISK; CLINICAL TRIAL; GLEASON SCORE; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 31; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; UTERINE CERVIX CANCER;

ANTIBODIES, VIRAL; CASE-CONTROL STUDIES; CLINICAL TRIALS AS TOPIC; HUMAN PAPILLOMAVIRUS 16; HUMAN PAPILLOMAVIRUS 18; HUMANS; MALE; PAPILLOMAVIRUS INFECTIONS; PROSTATIC NEOPLASMS; RISK FACTORS; SEROEPIDEMIOLOGIC STUDIES;

EID: 76149119429     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-09-1080     Document Type: Article

References (22)

1. Strickler HD, Goedert JJ. Sexual behavior and evidence for an infectious cause of prostate cancer. Epidemiol Rev 2001;23:144-51.
2. Taylor ML, Mainous AG III, Wells BJ. Prostate cancer and sexually transmitted diseases: a meta-analysis. Fam Med 2005;37:506-12.
3. Korodi Z, Dillner J, Jellum E, et al. Human papillomavirus 16, 18, and 33 infections and risk of prostate cancer: a Nordic nested case-control study. Cancer Epidemiol Biomarkers Prev 2005;14:2952-5.
4. Sutcliffe S, Giovannucci E, Gaydos CA, et al. Plasma antibodies against Chlamydia trachomatis, human papillomavirus, and human herpesvirus type 8 in relation to prostate cancer: a prospective study. Cancer Epidemiol Biomarkers Prev 2007;16:1573-80.
5. Sitas F, Urban M, Stein L, et al. The relationship between anti-HPV-16 IgG seropositivity and cancer of the cervix, anogenital organs, oral cavity and pharynx, oesophagus and prostate in a Black South African population. Infect Agent Cancer 2007;2:6.
6. Huang WY, Hayes R, Pfeiffer R, et al. Sexually transmissible infections and prostate cancer risk. Cancer Epidemiol Biomarkers Prev 2008;17:2374-81.
7. Bergh J, Marklund I, Gustavsson C, et al. No link between viral findings in the prostate and subsequent cancer development. Br J Cancer 2007;96:137-9.
8. Leskinen MJ, Vainionp R, Syrjnen S, et al. Herpes simplex virus, cytomegalovirus, and papillomavirus DNA are not found in patients with chronic pelvic pain syndrome undergoing radical prostatectomy for localized prostate cancer. Urology 2003;61:397-401.
9. Balis V, Sourvinos G, Soulitzis N, et al. Prevalence of BK virus and human papillomavirus in human prostate cancer. Int J Biol Markers 2007;22:245-51.
10. Sfanos KS, Sauvageot J, Fedor HL, et al. A molecular analysis of prokaryotic and viral DNA sequences in prostate tissue from patients with prostate cancer indicates the presence of multiple and diverse microorganisms. Prostate 2008;68:306-20.
11. Gazzaz FS, Mosli HA. Lack of detection of human papillomavirus infection by hybridization test in prostatic biopsies. Saudi Med J 2009; 30:633-7.
12. Silvestre RV, Leal MF, Demachki S, et al. Low frequency of human papillomavirus detection in prostate tissue from individuals from northern Brazil. Mem Inst Oswaldo Cruz 2009;104:665-7.
13. Goodman PJ, Tangen CM, Crowley JJ, et al. Implementation of the Prostate Cancer Prevention Trial (PCPT). Control Clin Trials 2004;25: 203-22.
14. Sutcliffe S, Alderete JF, Till C, et al. Trichomonosis and subsequent risk of prostate cancer in the Prostate Cancer Prevention Trial. Int J Cancer 2009;124:2082-7.
15. Viscidi RP, Ahdieh-Grant L, Clayman B, et al. Serum immunoglobulin G response to human papillomavirus type 16 virus-like particles in human immunodeficiency virus (HIV)-positive and risk-matched HIV-negative women. J Infect Diseases 2003;187:194-205.
16. Strickler HD, Schiffman MH, Shah KV, et al. A survey of human papillomavirus 16 antibodies in patients with epithelial cancers. Eur J Cancer Prev 1998;7:305-13.
17. Strickler HD, Burk R, Shah K, et al. A multifaceted study of human papillomavirus and prostate carcinoma. Cancer 1998;82:1118-25.
18. Hayes RB, Pottern LM, Strickler H, et al. Sexual behaviour, STDs and risks for prostate cancer. Br J Cancer 2000;82:718-25.
19. Adami HO, Kuper H, Andersson SO, Bergstrom R, Dillner J. Prostate cancer risk and serologic evidence of human papilloma virus infection: a population-based case-control study. Cancer Epidemiol Biomarkers Prev 2003;12:872-5.
20. Rosenblatt KA, Carter JJ, Iwasaki LM, Galloway DA, Stanford JL. Serologic evidence of human papillomavirus 16 and 18 infections and risk of prostate cancer. Cancer Epidemiol Biomarkers Prev 2003;12: 763-8.
21. Hisada M, Rabkin CS, Strickler HD, et al. Human papillomavirus antibody and risk of prostate cancer. JAMA 2000;283:340-1.
22. Dillner J, Knekt P, Boman J, et al. Sero-epidemiological association between human-papillomavirus infection and risk of prostate cancer. Int J Cancer 1998;75:564-7.